Partner Antoinette Konski was quoted in an FDA Week article on March 13, 2014 titled, “Gene Patent Experts Disagree About Patent Office’s Post-Myriad Guide.” The article discusses how experts are split on new guidance from the U.S. Patent and Trademark Office outlining when products that use naturally occurring genetic materials are patentable following a Supreme Court decision invalidating patents on naturally occurring DNA. Konski was quoted saying, “The guidance does not provide clear examples of marked differences that relate to current technology.”
People
Related News
13 December 2024
In the News
Brian Tomkins Featured Across Legal Press for Arrival to Foley
Foley & Lardner LLP partner Brian Tomkins is featured across legal press for his recent arrival to the firm.
11 December 2024
In the News
Nathan Beaver Discusses GLP-1 Compounding, FDA Deliberations
Foley & Lardner LLP partner Nathan Beaver discussed the ongoing deliberations at the U.S. Food and Drug Administration over a popular class of drugs in the PharmaVoice article, "GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?"
11 December 2024
In the News
Brian Wheeler Quoted on Dealmaking in GP-led Secondaries Market
Foley & Lardner LLP partner Brian Wheeler commented in the Pitchbook article, "GP-led secondaries to end 2024 with new record," assessing the prospects for dealmaking in the space heading into 2025.